| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H25BrN2O3S |
| Molecular Weight | 477.415 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)C1=C(CSC2=CC=CC=C2)N(C)C3=C1C(CN(C)C)=C(O)C(Br)=C3
InChI
InChIKey=KCFYEAOKVJSACF-UHFFFAOYSA-N
InChI=1S/C22H25BrN2O3S/c1-5-28-22(27)20-18(13-29-14-9-7-6-8-10-14)25(4)17-11-16(23)21(26)15(19(17)20)12-24(2)3/h6-11,26H,5,12-13H2,1-4H3
| Molecular Formula | C22H25BrN2O3S |
| Molecular Weight | 477.415 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Umifenovir or arbidol (ethyl-6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-[(phenylthio)methyl]-indole-3-carboxylate hydrochloride monohydrate) is a Russian-made potent broad-spectrum antiviral with demonstrated activity against a number of enveloped and non-enveloped viruses.For both viral infections the anti-viral mechanism involves umifenovir inhibition of virus-mediated fusion with target membrane and a resulting block of virus entry into target cells. Arbidol was shown to have effects on nonspecific defense factors, on its capacity to induce interferon and activate phagocytes in particular. Arbidol-treated patients with lower baseline immunity showed improvement in immunological parameters (in the counts of CD4 and CD8 lymphocytes, B lymphocytes, in the levels of serum immunoglobulins). Arbidol produces a high preventive and therapeutical effects in influenza A and B and other acute respiratory viral infections, prevents postinfluenza complications, reduces the incidence of exacerbations of chronic diseases in postinfluenza patients. In influenza, the therapeutical efficiency of the drug appears as decreases in intoxication, the severity of catarrhal syndrome, shorter fever and disease in general. Arbidol is beneficial for patients with secondary immunodeficiency, in those with recurrent herpes infection or chronic bronchitis.
Originator
Approval Year
AUC
Doses
PubMed
Patents
Sample Use Guides
Directions for Use:
For internal use, to be taken on an empty
stomach.
Single dose amount: Children 2 - 7 years, 50 mg;
7 – 12 years, 100 mg; 12 – adult, 200 mg (1 - 200 mg
capsule, 2 – 100 mg capsules, or 4 - 50 mg capsules).
For non-specific prophylaxis: During direct contact
with patients with influenza or RSV, children 2 – 7,
50 mg; children 7 – 12, 100 mg; 12 to adult, 200 mg,
once a day for 10 to 14 days.
During influenza or other RSV epidemics, or in order
to prevent exacerbation of chronic bronchitis, or
recurrent herpes infection, the dosage is children 2 –
7, 50 mg; children 7 – 12, 100 mg; and over 12 to
adult, 200 mg, twice a week for three weeks.
For SARS prophylaxis (during contact with SARS
patients), the dosage for children over 12 – adult is
200 mg once a day; for children from 7 to 12, 100
mg, taken before food, once a day for 12 – 14 days.
For prophylaxis against postoperative complications:
children 2 – 7, 50 mg; children 7 – 12, 100 mg;
children over 12 – adult, 200 mg 48 hours before the
procedure, then from 2 to 5 days after the procedure.
For treatment of illness: For influenza, or other
uncomplicated RSV, children 2 – 7, 50 mg; children
7 – 12, 100 mg, and children over 12 and adults, 200
mg, 4 times a day (every 6 hours) for 5 days.
For influenza with complications (bronchitis,
pneumonia), children 2 – 7, 50 mg; children 7 – 12,
100 mg; children over 12 and adults, 200 mg, 4 times
a day (every 6 hours) for 5 days, then one dose per
week for the next four weeks.
For Severe Acute Respiratory Syndrome (SARS), in
children over 12 and adults, 200 mg twice a day for 8
– 10 days.
For chronic bronchitis or herpes-type infections, in
children 2 – 7 years, 50 mg; children 7 – 12, 100 mg;
children over 12 and adults, 200 mg 4 times a day
(every 6 hours) for 5 – 7 days; thereafter, one dose
twice a week for the next 4 weeks.
For treatment of acute intestinal infections of the
rotavirus-type, in children over 2 years old, give 50
mg; children 7 – 12, 100 mg; and children over 12,
200 mg, four times a day (every 6 hours) for 5 days.
Route of Administration:
Oral
